Turns out those GLP-1 drugs, the ones everyone's talking about for weight loss, might be doing a lot more behind the scenes. New research suggests that the amount of weight people lose on medications like Ozempic and Wegovy directly correlates to a significantly lower risk of some pretty serious health issues.
Basically, the more weight you shed with these drugs, the better your chances of dodging things like sleep apnea, chronic kidney disease, and even heart failure. On the flip side, patients who actually gained weight on the meds generally saw their health outcomes head in the wrong direction. Because, apparently, that's how physics works.
The findings, presented at the European Congress on Obesity in Istanbul, looked at real-world data from over 88,000 patients in the U.S. who started GLP-1 treatments between 2021 and 2024. Researchers tracked their Body Mass Index (BMI) changes for the first year, then compared those changes to their health outcomes up to June 2025.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe Numbers Don't Lie
Among the participants, the average age was 57.5, and the average BMI was 34.7 kg/m2 (which is considered obese). About 61% also had type 2 diabetes. While about half of them stopped their treatment within a year, the study looked at everyone, regardless of whether they stuck with it.
During that first year, 27% of patients lost less than 5% of their BMI. Another 22.4% lost between 5% and 10%. A solid 14.1% dropped 10% to 15%, and a rather impressive 15.8% lost at least 15% of their BMI. The plot twist? A full 20.8% of patients actually saw their BMI increase.
Over the next 11 months, the study tracked new diagnoses. For every 1,000 people per year, there were 21.4 cases of osteoarthritis, 21.1 cases of chronic kidney disease (CKD), and 20.3 cases of obstructive sleep apnea (OSA). Heart failure clocked in at 3.9 cases.
Now, for the really interesting bit: Compared to those who lost less than 5% of their BMI, patients who lost at least 15% saw dramatically reduced risks:
- 37% lower risk of osteoarthritis
- 30% lower risk of CKD
- A staggering 69% lower risk of OSA (that's almost two-thirds!)
- 32% lower risk of heart failure (though this one wasn't statistically significant, it's still worth noting).
And for those whose BMI went up? They faced a 10% higher risk of osteoarthritis, 14% higher for CKD, 22% higher for OSA, and a whopping 69% higher risk of heart failure. Which, if you think about it, is both impressive and slightly terrifying.
The takeaway? Losing weight, and keeping it off, with these GLP-1 treatments isn't just about fitting into old jeans. It's about significantly lowering your risk for a whole host of serious health problems. Your body, it seems, sends its regards.
